Key Takeaways Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

Jacob Elkins has left Sarepta to take the CMO job at AIRNA, the RNA editing shop that disclosed a $155 million Series ...

Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has temporarily halted recruitment and dosing in three clinical studies of its ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

Shares of Sarepta, based in Cambridge, Massachusetts, dropped more than 27% on Tuesday, closing at about $73 per share. Elevidys, which costs $3.2 million for a one-time infusion, was the first gene ...

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The ...

Explore Solid Biosciences’ potential with promising SGT-003 trial results for DMD, strong financials, and market recovery ...

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be oversold. Next earnings are expected to be released in 27 days.